

Article

Facile Access to 2-Selenoxo-1,2,3,4-tetrahydro-4-quinazolinone Scaffolds and Corresponding Diselenides via Cyclization between Methyl Anthranilate and Isoselenocyanates: Synthesis and Structural Features

Vladimir K. Osmanov¹, Evgeniy V. Chipinsky¹, Victor N. Khrustalev^{2,3}, Alexander S. Novikov^{2,4}, Rizvan Kamiloglu Askerov⁵, Alexander O. Chizhov³, Galina N. Borisova¹, Alexander V. Borisov¹, Maria M. Grishina², Margarita N. Kurasova², Anatoly A. Kirichuk², Alexander S. Peregudov⁶, Andreii S. Kritchenkov² and Alexander G. Tskhovrebov^{2,7,*}

- ¹ Department of Chemistry, R.E. Alekseev Nizhny Novgorod State Technical University, Minin St., 24, 603155 Nizhny Novgorod, Russia
- ² Research Institute of Chemistry, Peoples' Friendship University of Russia, Miklukho-Maklaya St., 6, 117198 Moscow, Russia
- ³ N.D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, Leninsky Prosp., 47, 119334 Moscow, Russia
- ⁴ Institute of Chemistry, Saint Petersburg State University, Universitetskaya Nab., 7/9, 199034 Saint Petersburg, Russia
 - Department of Organic Chemistry, Baku State University, Z. Xalilov, 23, Baku 1148, Azerbaijan
- ⁶ Institute of Organoelement Compounds of the Russian Academy of Sciences, Vavilov St., 28, 119991 Moscow, Russia
- ⁷ N.N. Semenov Federal Research Center for Chemical Physics, Russian Academy of Sciences, Ul. Kosygina, 4, 119991 Moscow, Russia
- Correspondence: tskhovrebov-ag@rudn.ru

Abstract: A practical method for the synthesis of 2-selenoxo-1,2,3,4-tetrahydro-4-quinazolinone was reported. The latter compounds were found to undergo facile oxidation with H₂O₂ into corresponding diselenides. Novel organoselenium derivatives were characterized by the ¹H, ⁷⁷Se, and ¹³C NMR spectroscopies, high-resolution electrospray ionization mass spectrometry, IR, elemental analyses (C, H, N), and X-ray diffraction analysis for several of them. Novel heterocycles exhibited multiple remarkable chalcogen bonding (ChB) interactions in the solid state, which were studied theoretically.

Keywords: quinazolinones; selenium; heterocycles; chalcogen bonding; cyclization; isoselenocyanates

1. Introduction

Quinazolinones are an important class of heterocycles, which are widespread in natural alkaloids and synthetic biologically active compounds [1]. Quinazolinone derivatives are known to exhibit hypotensive, anticonvulsant, anti-inflammatory, antibacterial, antimalarial, fungicidal effects, and antiproliferative activity [2–9]. Interestingly, the introduction of the S or Se atoms in 2- or 4-positions of the quinazolinone core results in the enhancement of the anticancer activity [5,6,10–15].

There are several approaches to the synthesis of heterocyclic thiones and selones described in the literature. The first one includes halogen to sulfur or selenium substitution employing hydrosulphide or hydroselenide or thio- or selenourea [16–19]. The Se atom can also be conveniently introduced via substitution of the SMe moiety on treatment with NaSeH [20]. Another widely spread approach to the synthesis of sulfur-containing derivatives of quinazolinones involves the reaction between o-aminonitriles or o-aminocarboxylates and isothiocyanates or thiourea. However, this approach has been



Citation: Osmanov, V.K.; Chipinsky, E.V.; Khrustalev, V.N.; Novikov, A.S.; Askerov, R.K.; Chizhov, A.O.; Borisova, G.N.; Borisov, A.V.; Grishina, M.M.; Kurasova, M.N.; et al. Facile Access to 2-Selenoxo-1,2,3,4tetrahydro-4-quinazolinone Scaffolds and Corresponding Diselenides via Cyclization between Methyl Anthranilate and Isoselenocyanates: Synthesis and Structural Features. *Molecules* 2022, *27*, 5799. https:// doi.org/10.3390/molecules27185799

Academic Editors: Ting Wang and Xin Huang

Received: 16 August 2022 Accepted: 2 September 2022 Published: 7 September 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). studied little for the preparation of derivatives of quinazolin-2(1H)-selones, which is probably due to the lower stability and synthetic availability of isoselenocyanates [21,22]. It should be noted that interest in chacogen-containing derivatives of quinazolinones arises due to their potential applications in supramolecular chemistry. Halogen and chalcogen bonding (ChB) is an area of increasing interest, and these weak interactions are often employed for various applications [23–33].

Following our interest in chalcogen heterocycles [34,35,35–37] and noncovalent interactions [38–47], here we reported a convenient synthesis of 2-selenoxo-1,2,3,4-tetrahydro-4quinazolinones via cyclization reaction between methyl anthranilate and isoselenocyanates. Moreover, we demonstrated that 2-selenoxo-1,2,3,4-tetrahydro-4-quinazolinones undergo facile oxidation under mild conditions to give corresponding diselenides.

2. Results and Discussion

The addition of isoselenocyanates **2a–g** to a solution of methyl anthranilate **1** in ethanol under reflux allowed the preparation of corresponding 2-selenoxo-1,2,3,4-tetrahydro-4-quinazolinones **3a–g** in high yields (Scheme 1).



Scheme 1. Synthesis of 3a–g.

The structures of all new compounds were confirmed by the ¹H, ⁷⁷Se, and ¹³C NMR spectroscopies; high-resolution electrospray ionization mass spectrometry (HRESI–MS); IR; the elemental analyses (C, H, N); and X-ray diffraction analysis for **3b**, **3f**, and **3g** (Figure 1). Compounds **3b**, **3f**, and **3g** could be recrystallized to furnish monocrystals, suitable for analysis by single crystal X-ray crystallography. The structural investigations confirmed the formation of 2-selenoxo-1,2,3,4-tetrahydro-4-quinazolinones. The plausible mechanism for the formation of **3a–g** is depicted in Scheme 1 and is similar to what was observed in the S analogs [15].



Figure 1. Ball-and-stick representations of **3b**, **3f**, and **3g**. Se…Se ChB for **3f** is depicted as a dashed line. Grey and light grey spheres represent carbon and hydrogen atoms, respectively.

Structural investigations revealed that the 2-selenoxo-1,2,3,4-tetrahydro-4quinazolinone fragment in **3b**, **3f**, and **3g** is virtually planar, and the C=Se distances are within the typical range for the corresponding single bond values. Interestingly, compound **3f** exhibited unsymmetrical supramolecular dimers via type II Se…Se ChB (Figure 1), while **3b** and **3f** were not engaged in ChB, arguably due to the prevalence of other weak interactions in the solid state. Theoretical calculations on the type II Se…Se ChB for compound **3f** are given here further.

When we attempted to recrystallize **3c** from ethanol, its aerobic oxidation coupled with the diselenide formation took place. Similar oxidations were observed earlier in the literature [22,48,49]. We were able to achieve synthetically viable oxidation for **3a–g** to furnish **4a–g** in good yields employing hydrogen peroxide as an oxidant (Scheme 2).



Scheme 2. Synthesis of 4a–g.

Compounds **4a–g** are poorly soluble in common organic solvents; however, we managed to obtain single crystals of **4b** and **4c**, suitable for X-Ray analysis (Figure 2).



Figure 2. Ball-and-stick representations of **4b** and **4c** demonstrating intramolecular Se…N ChB, depicted as dashed lines. Grey and light grey spheres represent carbon and hydrogen atoms, respectively.

Both compounds **4b** and **4c** exhibited a pair of intramolecular Se…N ChB (Figure 2). Cambridge Structural Database search revealed that it contained only four other published structures (**5** [49], **6** [50], **7** [51,52], and **8** [52]), which featured such a remarkable pair of intramolecular X…N (X = S, Se, Te) ChB (Figure 3).



Figure 3. Ball-and-stick representations of **5–8** demonstrating intramolecular Se…N ChB, depicted as dashed lines. Grey and light grey spheres represent carbon and hydrogen atoms, respectively.

Compound **5** is a dibenzimidazole diselenide, as are **4b** and **4c**, which features two intramolecular Se…N ChB. For **6**, the situation is slightly more complicated: each Se atom is involved in two intramolecular Se…N ChB, and overall, the molecule features four Se…N ChB (Figure 3). Compounds **7** [51,52] and **8** [52], which were reported earlier, also featured intramolecular ChB, analogously to **4b** and **4c**.

In order to theoretically study chalcogen bonds Se…Se, Se…N, and Te…N observed in the X-ray structures **3f**, **4b**, **4c**, **5**, **6**, **7**, and **8**, the DFT calculations followed by the topological analysis of the electron density distribution within the QTAIM approach [53] were carried out for model supramolecular associates (see Computational details and Table S1 in Supplementary Materials). The results of the QTAIM analysis are summarized in Table 1. The contour line diagrams of the Laplacian of electron density distribution $\nabla^{2\rho}(\mathbf{r})$, bond paths, and selected zero-flux surfaces; visualization of electron localization function (ELF); and reduced density gradient (RDG) analyses for contacts Se…Se, Se…N, and Te…N in the X-ray structures **3f**, **4b**, **4c**, **5**, **6**, **7**, and **8** are shown in Figures 4–10; the visualization of these noncovalent interactions in 3D using NCI analysis technique [54] is shown in Figure 11.

Table 1. Values of the density of all electrons— $\rho(\mathbf{r})$, Laplacian of electron density— $\nabla^2 \rho(\mathbf{r})$ and appropriate λ_2 eigenvalues, energy density— H_b , potential energy density— $V(\mathbf{r})$, and Lagrangian kinetic energy— $G(\mathbf{r})$ (a.u.) at the bond critical points (3, -1), corresponding to contacts Se…Se, Se…N, and Te…N in the X-ray structures **3f**, **4b**, **4c**, **5**, **6**, **7**, and **8**, and approximately estimated strength for these interactions E_{int} (kcal/mol) [55].

Contact *	ρ _(r)	$ abla^2 ho(\mathbf{r})$	λ_2	H _b	V(r)	G(r)	${ m E_{int}}pprox-{ m V(r)/2}$
3f							
Se…Se 3.717 Å	0.007	0.020	-0.007	0.001	-0.003	0.004	0.9
4b							
Se–Se 2.360 Å	0.102	-0.052	-0.102	-0.043	-0.074	0.031	23.2
Se…N 2.899 Å	0.017	0.061	-0.017	0.002	-0.012	0.014	3.8
4c							
Se–Se 2.357 Å	0.102	-0.052	-0.102	-0.044	-0.075	0.031	23.5
Se…N 2.870 Å	0.018	0.063	-0.018	0.001	-0.013	0.014	4.1
5							
Se–Se 2.359 Å	0.102	-0.054	-0.102	-0.044	-0.074	0.030	23.2
Se…N 2.792 Å	0.021	0.070	-0.021	0.001	-0.015	0.016	4.7
6							
Se–Se 2.433 Å	0.095	-0.048	-0.095	-0.039	-0.066	0.027	20.7
Se…N 2.733 Å	0.024	0.080	-0.024	0.001	-0.018	0.019	5.6
Se…N 2.479 Å	0.042	0.115	-0.042	-0.003	-0.035	0.032	11.0
7							
Se–Se 2.343 Å	0.104	-0.052	-0.104	-0.045	-0.077	0.032	24.2
Se…N 2.925 Å	0.017	0.059	-0.017	0.002	-0.011	0.013	3.5
8							
Te-Te 2.723 Å	0.072	0.138	-0.072	-0.018	-0.031	0.013	9.7
Te…N 3.082 Å	0.016	0.056	-0.016	0.001	-0.010	0.011	3.1

* The Bondi's (shortest) Van der Waals radii for Te, Se, and N atoms are 2.00, 1.90, and 1.55 Å, respectively [56].



Figure 4. Cont.



Figure 4. Contour line diagram of the Laplacian of electron density distribution $\nabla^2 \rho(\mathbf{r})$, bond paths, and selected zero-flux surfaces (**top**), visualization of electron localization function (ELF, **center**), and reduced density gradient (RDG, **bottom**) analyses for contact Se…Se (chalcogen bond) in the X-ray structure **3f**. Bond critical points (3, –1) are shown in blue, nuclear critical points (3, –3)—pale brown, ring critical points (3, +1)—orange, bond paths are shown as pale brown lines, length units—Å, and the color scale for the ELF and RDG maps is presented in a.u.



Figure 5. Contour line diagram of the Laplacian of electron density distribution $\nabla^2 \rho(\mathbf{r})$, bond paths, and selected zero-flux surfaces (**left**), visualization of electron localization function (ELF, **center**), and reduced density gradient (RDG, **right**) analyses for contacts Se–Se and Se…N in the X-ray structure **4b**. Bond critical points (3, –1) are shown in blue, nuclear critical points (3, –3)—pale brown, ring critical points (3, +1)—orange, bond paths are shown as pale brown lines, length units—Å, and the color scale for the ELF and RDG maps is presented in a.u.



Figure 6. Contour line diagram of the Laplacian of electron density distribution $\nabla^2 \rho(\mathbf{r})$, bond paths, and selected zero-flux surfaces (**left**), visualization of electron localization function (ELF, **center**), and reduced density gradient (RDG, **right**) analyses for contacts Se–Se and Se…N in the X-ray structure **4c**. Bond critical points (3, –1) are shown in blue, nuclear critical points (3, –3)—pale brown, ring critical points (3, +1)—orange, bond paths are shown as pale brown lines, length units—Å, and the color scale for the ELF and RDG maps is presented in a.u.



Figure 7. Contour line diagram of the Laplacian of electron density distribution $\nabla^2 \rho(\mathbf{r})$, bond paths, and selected zero-flux surfaces (**left**), visualization of electron localization function (ELF, **center**), and reduced density gradient (RDG, **right**) analyses for contacts Se–Se and Se…N in the X-ray structure **5**. Bond critical points (3, –1) are shown in blue, nuclear critical points (3, –3)—pale brown, ring critical points (3, +1)—orange, bond paths are shown as pale brown lines, length units—Å, and the color scale for the ELF and RDG maps is presented in a.u.



Figure 8. Contour line diagram of the Laplacian of electron density distribution $\nabla^2 \rho(\mathbf{r})$, bond paths, and selected zero-flux surfaces (**left**), visualization of electron localization function (ELF, **center**), and reduced density gradient (RDG, **right**) analyses for contacts Se–Se and Se…N in the X-ray structure **6**. Bond critical points (3, –1) are shown in blue, nuclear critical points (3, –3)—pale brown, ring critical points (3, +1)—orange, bond paths are shown as pale brown lines, length units—Å, and the color scale for the ELF and RDG maps is presented in a.u.



Figure 9. Contour line diagram of the Laplacian of electron density distribution $\nabla^2 \rho(\mathbf{r})$, bond paths, and selected zero-flux surfaces (**left**), visualization of electron localization function (ELF, **center**), and reduced density gradient (RDG, **right**) analyses for contacts Se–Se and Se…N in the X-ray structure **7**. Bond critical points (3, –1) are shown in blue, nuclear critical points (3, –3)—pale brown, ring critical points (3, +1)—orange, bond paths are shown as pale brown lines, length units—Å, and the color scale for the ELF and RDG maps is presented in a.u.



Figure 10. Contour line diagram of the Laplacian of electron density distribution $\nabla^2 \rho(\mathbf{r})$, bond paths, and selected zero-flux surfaces (**left**), visualization of electron localization function (ELF, **center**) and reduced density gradient (RDG, **right**) analyses for contacts Te–Te and Te…N in the X-ray structure **8**. Bond critical points (3, –1) are shown in blue, nuclear critical points (3, –3)—pale brown, ring critical points (3, +1)—orange, bond paths are shown as pale brown lines, length units—Å, and the color scale for the ELF and RDG maps is presented in a.u.



Figure 11. Visualization of noncovalent interactions Se…Se, Se…N, and Te…N in 3D using NCI analysis technique in model supramolecular associates **3f**, **6**, **7**, and **8**.

The QTAIM analysis of model supramolecular associates demonstrates the presence of bond critical points (3, -1) for contacts Se…Se, Se…N, and Te…N in the X-ray structures 3f, 4b, 4c, 5, 6, 7, and 8 (Table 1 and Figures 4–10). The low magnitude of the electron density, positive values of the Laplacian of electron density, and very close to zero energy density in bond critical points (3, -1) for chalcogen bonds Se...Se (3f) and Se...N (4b, 4c, 5, 6, and 7) or Te \cdots N (8) in studied model supramolecular associates, as well as their estimated strength, are typical for noncovalent interactions involving chalcogen atoms [34,35,35–37,57–62], in contrast with these descriptors (viz. relatively large magnitude of the electron density, negative Laplacian of electron density, and large negative energy density) for covalent bonds Se–Se and Te–Te in **4b**, **4c**, **5**, **6**, **7**, and **8**. The sign of λ_2 can be utilized to distinguish bonding (attractive, $\lambda_2 < 0$) interactions from nonbonding ones (repulsive, $\lambda_2 > 0$) [54,63], which allows us to conclude that chalcogen bonds contact Se...Se, Se...N, and Te...N in the X-ray structures 3f, 4b, 4c, 5, 6, 7, and 8 are attractive in nature and purely noncovalent (in all cases, except Se...N interactions (2.479 Å) in 6, which has some covalent contribution), because the balance between the Lagrangian kinetic energy $G(\mathbf{r})$ and potential energy density $V(\mathbf{r})$ at the appropriate bond critical points (3, -1) for these contacts is $-G(\mathbf{r})/V(\mathbf{r}) > 1$ [64].

3. Materials and Methods

Methyl anthranilate (Acros Organics, Belgium) was used in this work without additional purification. The isoselenocyanates **2** \mathbf{a} – \mathbf{g} used in this work were obtained by the literature method [65]. Isoselenocyanates **2b**, **c**, **g** were purified by recrystallization from hexane at -20 °C. Ethanol was dried by distillation over CaO and CaH₂.

All melting points were determined with a "Stuart SMP3" melting point apparatus. Infrared spectra were recorded on the "Shimadzu IR Prestige-21" (Kyoto, Japan) instrument in KBr disk (4000–400 cm⁻¹). High-resolution mass spectra (HR-MS) were measured on a "Bruker micrOTOF II" (Karlsruhe, Germany) instrument using electrospray ionization (ESI). The measurements were performed in a positive ion mode (interface capillary voltage –4500 V); mass range from m/z 50 to m/z 30 0 0 Da; internal calibration was performed with Electrospray Calibrant Solution («Agilent Tuning Mix», «Agilent»). The most intensive peak in the isotopic pattern was reported. A syringe injection was used for solutions in acetonitrile (flow rate 5 McL/min). Nitrogen was applied as a dry gas; interface temperature was set at 180 °C.

¹H, COSY, ¹³C-NMR, DEPT, HSQC, and HMBC spectra compounds **3a–f** were measured on an "Agilent DD2 400" spectrometer (400 MHz for ¹H and 100.60 MHz for ¹³C, Santa Clara, CA, USA) using DMSO-d6 as the NMR solvents. Chemical shifts were indicated in parts per million (ppm) relative to tetramethylsilane as an internal standard. The ⁷⁷Se-NMR spectra compound **3a-f** were measured on an "Agilent DD2 400" spectrometer at 76.30 MHz using diphenylselenide as a standard. The ¹⁹F-NMR spectra compound 3e were measured on an "Agilent DD2 400" spectrometer at 376.30 MHz using trichlorofluoromethane as a standard. The ¹H, COSY, ¹³C, JMODECHO, HSQC, and HMBC compounds 3g were measured on a "Bruker AvanceTM 600" (Karlsruhe, Germany) spectrometer (600 MHz for ¹H and 150.925 MHz for ¹³C) using DMSO-d6 as the NMR solvents. The ¹H, COSY, ¹³C, JMODECHO, HSQC, and HMBC compounds **4a–g** were measured on a "Bruker AvanceTM 500" spectrometer (500 MHz for ¹H and 125.72 MHz for ¹³C) using DMSO- d6 as the NMR solvents. The ⁷⁷Se-NMR spectra compounds, **3g** and **4a–g**, were measured on a "Bruker AvanceTM 400" spectrometer at 76.35 MHz and referenced to diphenylselenide, using DMSO- *d*6 as the NMR solvents. The ¹⁹F-NMR spectra compounds, **3g**, **4e**, and **4g**, were measured on a "Bruker AvanceTM 300" spectrometer at 282.38 MHz and referenced to trichlorofluoromethane, using DMSO-d6 as NMR solvent.

3.1. Synthetic Part

Synthesis of compounds 3a–g (general method). To a solution (0.01 mol) of methyl anthranilate, 1 in 100 mL of absolute ethanol (0.01 mol) of the corresponding isoselenocyanate 2 a–g in 20 mL of absolute ethanol was added, boiled for 6 h, then cooled to 0 °C. Precipitates precipitated from the solution were separated by filtration, washed with ethanol (2 × 25 mL), and dried at 40 °C.



3-phenyl-2-selenoxo-2,3-dihydroquinazolin4(1*H*)-one. Light yellow solid (47%), mp 235 °C. Anal. Calcd. for C₁₄H₁₀N₂OSe: C 55.82; H 3.35; N 9.30. Found: C 55.72; H 3.30; N 9.38. ESI⁺-MS, *m*/*z*: calcd for [C₁₄H₁₀N₂OSe + H]⁺ 303.0031, found 303.0036 [C₁₄H₁₀N₂OSe + H]⁺. IR (KBr, selected bands, sm⁻¹): 3244, 1664, 1621, 1528, 1488, 1266, 1189, 759, 691. ¹H NMR (400 MHz, DMSO-*d*₆), δ (ppm): 13.46 (bs, 1H, NH), 7.93 (dd, *J* = 8.0, *J* = 1.0, 1H, H-5), 7.77 (t, 1H, H-7), 7.51 (d, *J* = 8.0 Hz, 1H, H-8), 7.46 (m, 2H, Ph), 7,39 (m, 2H, Ph and H-6), 7.24 (m, 2H, Ph). ¹³C NMR (100.60 MHz, DMSO-*d*₆), δ (ppm): 176.4 (C=Se), 159.3 (C=O), 141.2 (C, Ph), 140.4 (C-8a), 136.2 (C-7), 129.5 (2CH, Ph), 129.3 (2CH, Ph), 128.7 (CH, Ph), 127.9 (C-5), 125.4 (C-6), 117.2 (C-4a), 117.2 (C-4a), 116.5 (C-8). ⁷⁷Se NMR (76.30 MHz, DMSO-*d*₆), δ (ppm): 462.0 (s).



3-(2-methylphenyl)-2-selenoxo-2,3-dihydro-quinazolin- 4(1*H*)-one. Light brown solid (54%), mp 210 °C. Anal. Calcd. for C₁₅H₁₂N₂OSe: 57.15; H 3.84; N 8.89. Found: C 57.35; H 3.72; N 8.78. ESI⁺-MS, *m*/*z*: calcd for [C₁₅H₁₂N₂OSe + H]⁺ 317.0188, found 317.0184 [C₁₅H₁₂N₂OSe + H]⁺. IR (KBr, selected bands, sm⁻¹): 3241, 1702, 1619, 1520, 1410, 1262, 1189, 753. ¹H NMR (400 MHz, DMSO-*d*₆), δ (ppm): 13.59 (bs, 1H, NH), 7.95 (d, *J* = 7.5, 1H, H-5), 7.80 (m, 1H, H-7), 7.55 (d, *J* = 8.0, 1H, H-8), 7.41 (t, 1H, H-6), 7,26-7,33 (m, 3H, Ar), 7.20 (d, *J* = 10.0, 1H, Ar), 2.03 (s, 3H, CH₃). ¹³C NMR (100.60 MHz, DMSO-*d*₆), δ (ppm): 175.7 (C=Se), 158.7 (C=O), 140.5 (C-8a), 140.0 (C-1'), 136.4 (C-7), 135.5 (C-5'), 130.9 (C-3'), 129.4 (C-6'); 129.0 (C-4'), 128.0 (C-5), 127.2 (C-2'), 125.6 (C-6), 116.9 (C-4a), 116.6 (C-8), 17.55 (CH₃). ⁷⁷Se NMR (76.30 MHz, DMSO-*d*6), δ (ppm): 442.5 (s).



3-(2-methoxyphenyl)-2-selenoxo-2,3-dihydroquinazolin- 4(1*H*)-one. Yellow solid (56%), mp 250 °C. Anal. Calcd. for $C_{15}H_{12}N_2O_2Se: C 54.39$; H 3.65; N 8.46. Found: C 54.24; H 3.60; N 8.35. ESI⁺-MS, *m*/*z*: calcd for $[C_{15}H_{12}N_2O_2Se + H]^+$ 333.0137, found 333.0137 $[C_{15}H_{12}N_2O_2Se + H]^+$. IR (KBr, selected bands, sm⁻¹): 2946, 1711, 1621, 1533, 1420, 1265, 1190, 1020, 752. ¹H NMR (400 MHz, DMSO-*d*₆), δ (ppm): 13.53 (bs, 1H, NH), 7.93 (d, *J* = 8.0,

1H, H-5), 7.80 (m, 1H, H-7), 7.54 (d, J = 8.5, 1H, H-8), 7.40 (m, 2H, H-4' and H-6), 7.23 (dd, J = 8.0, J = 1.5, 1H, H-6'), 7.14 (d, J = 8.0, 1H, H-3'), 7.02 (t, 1H, H-5'), 3.70 (s, 3H, OCH₃). ¹³C NMR (100.60 MHz, DMSO- d_6), δ (ppm): 176.6 (C=Se), 158.7 (C=O), 154.7 (C-2'-O), 140.4 (C-8a), 136.4 (C-7), 130.6 (C-6'), 130.4 (C-4'), 129.4 (C-1'), 128.0 (C-5), 125.5 (C-6), 121.0 (C-5'), 116.7 (C-4a), 116.5 (C-8), 112.8 (C-3'), 56.18 (OCH₃). ⁷⁷Se NMR (76.30 MHz, DMSO- d_6), δ (ppm): 441.6 (s).



3-(3-methoxyphenyl)-2-selenoxo-2,3-dihydro-quinazolin- 4(1*H*)-one. Light beige solid (29%), mp 222 °C. Anal. Calcd. for C₁₅H₁₂N₂O₂Se: C 54.39; H 3.65; N 8.46. Found: C 54.31; H 3.61; N 8.40. ESI⁺-MS, *m*/*z*: calcd for $[C_{15}H_{12}N_2O_2Se + H]^+$ 333.0128, found 333.0137 $[C_{15}H_{12}N_2O_2Se + H]^+$. IR (KBr, selected bands, sm⁻¹): 2943, 1665, 1525, 1377, 1262, 759. ¹H NMR (400 MHz, DMSO-*d*₆), δ (ppm): 13.49 (bs, 1H, NH), 7.93 (dd, *J* = 8.0, *J* = 1.6, 1H, H-5), 7.78 (m, 1H, H-7), 7.53 (d, *J* = 8.4, 1H, H-8), 7.39 (m, 1H, H-6), 7.36 (t, 1H, H-5'), 6.97 (dd, *J* = 8.4, *J* = 2.5, 1H, H-6'), 6.90 (t, 1H, H-2'), 6.85 (d, *J* = 8.0, 1H, H-4'), 3.74 (s, 3H, OCH₃). ¹³C NMR (100.60 MHz, DMSO-*d*₆), δ (ppm): 176.3 (C=Se), 160.1 (C3'-O), 159.2 (C=O), 142.2 (C-1'), 140.4 (C-8a), 136.1 (C-7), 129.9 (C-5'), 127.9 (C-5), 125.4 (C-6), 121.7 (C-4'), 117.2 (C-4a), 116.5 (C-8), 115.5 (C-2'), 114.2 (C-6'), 55.7 (OCH₃). ⁷⁷Se NMR (76.30 MHz, DMSO-*d*₆), δ (ppm): 457.8 (s).



3-(2-fluorophenyl)-2-selenoxo-2,3-dihydroquina-zolin-4(1*H*)-one. Light green solid (38%), mp 212 °C. Anal. Calcd. for C₁₄H₉FN₂OSe: C 52.68; H 2.84; N 8.78. Found: C 52.62; H 2.87; N 8.67. ESI⁺-MS, *m*/*z*: calcd for [C₁₄H₉FN₂OSe + H]⁺ 320.9937, found 320.9941 [C₁₄H₉FN₂OSe + H]⁺. IR (KBr, selected bands, sm⁻¹): 3209, 1697, 1670, 1621, 1527, 1263, 1182. ¹H NMR (400 MHz, DMSO-*d*₆), δ (ppm): 13.71 (bs, 1H, NH), 7.96 (dd, *J* = 8.0, *J* = 1.2, 1H, H-5), 7.82 (m, 1H, H-7), 7.55 (d, *J* = 8.0, 1H, H-8), 7.28–7.52 (m, 5H, H-6, 4H Ar). ¹³C NMR

(100.60 MHz, DMSO-*d*₆), δ (ppm): 176.1 (C=Se), 158.7 (C=O), 157.6 (d, ¹*J* (¹³C-¹⁹F) = 310.5, C-2'-F), 140.4 (C-8a), 136.6 (C-7), 131.8 (C-5'), 131.3 (d, ³*J*(¹³C-¹⁹F) = 10.0, C-4'), 128.3 (d., ²*J*(¹³C-¹⁹F, C-1') = 16.5), 128.0 (C-5), 125.80 (C-6), 125.3 (d, ³*J*(¹³C-¹⁹F) = 4.5, C-6'), 116.7 (C-8), 116.5 (C-4a), 116.4 (d, ²*J*(¹³C-¹⁹F) = 24.3, C-3'). ¹⁹F NMR (376.30 MHz, DMSO-*d*6), δ (ppm): -122.96 (m, 1F). ⁷⁷Se NMR (76.30 MHz, DMSO-*d*6), δ (ppm): 447.0 (d, *J* = 2.5).



3-(2-chlorophenyl)-2-selenoxo-2,3-dihydroquinazolin-4(1*H*)-one. Beige solid (58%), mp 225 °C. Anal. Calcd. for C₁₄H₉ClN₂OSe: C 50.10; H 2.70; N 8.35. Found: C 50.16; H 2.67; N 8.27. ESI⁺-MS, *m*/*z*: calcd for [C₁₄H₉ClN₂OSe + H]⁺ 336.9639, found 336.9640 [C₁₄H₉ClN₂OSe + H]⁺. IR (KBr, selected bands, sm⁻¹): 3210, 1706, 1676, 1619, 1526, 1486, 1410, 1262, 1189, 758. ¹H NMR (400 Mm, Hz, DMSO-*d*₆), δ (ppm): 13.69 (bs, 1H, NH), 7.97 (d, *J* = 8.0, 1H, H-5), 7.82 (m, 1H, H-7), 7.60 (m, 1H, Ar), 7.55 (d, *J* = 8.0, 1H, H-8), 7.50 (m, 1H, Ar), 7.46 (m, 2H, Ar), 7.42 (t, 1H, H-6). ¹³C NMR (100.60 MHz, DMSO-*d*₆), δ (ppm): 175.7 (C=Se), 158.6 (C=O), 140.4 (C-8a), 138.2 (C Ar), 136.6 (C-7), 131.93 (C, Ar), 131.86 (CH, Ar), 130.8 (CH, Ar), 130.1 (CH, Ar), 128.5 (CH, Ar), 128.0 (C-5), 125.7 (C-6), 116.7 (C-8), 116.6 (C-4a). ⁷⁷Se NMR (76.30 MHz, DMSO-*d*6), δ (ppm): 450.0 (s).



3-[2-chloro-5-(trifluoromethyl)phenyl]-2-selenoxo-2,3-dihydroquinazolin-4(1*H*)-one. Beige solid (57%), mp 201 °C. Anal. Calcd. for $C_{15}H_8ClF_3N_2OSe$: C 44.63%, H 2.00%, N 6.94%. Found: C 44.52; H 2.06; N 6.87. ESI⁺-MS, *m*/*z*: calcd. for $[C_{15}H_8ClF_3N_2OSe + H]^+$ 404.9513, found 404.9502 $[C_{15}H_8ClF_3N_2OSe + H]^+$. IR (KBr, selected bands, sm⁻¹): 3164, 3113, 3019, 2958, 1718, 1701, 1621, 1534, 1328, 1190, 1175, 1132, 756. ¹H NMR (600 MHz, DMSO-*d*₆), δ (ppm): 13.86 (bs, 1H, NH), 8.10 (d, *J* = 1.9, 1H, H-6'), 8.00 (dd, *J* = 7.9, *J* = 0.9, 1H, H-5), 7.84–7.90 (m, 3H, H-7, H-3', H-4'), 7.58 (d, 1H, H-8), 7.46 (t, 1H, H-6).

¹³C NMR (150.925 MHz, DMSO-*d*₆), δ (ppm): 175.4 (C=Se), 158.6 (C=O), 140.5 (C-8a), 139.2 (C-2'), 136.81 (C-1'), 136.79(C-7), 131.4 (C-3'), 129.4 (k, ${}^{3}J({}^{13}C, {}^{19}F) = 3.2, C-6')$, 129.2 (k, ${}^{2}J({}^{13}C, {}^{19}F) = 32.8, C-5')$, 127.8 (k, ${}^{1}J({}^{13}C-{}^{19}F) = 272.6, CF_3$); 128.1 (C-5), 127.6 (d, ${}^{3}J({}^{13}C, {}^{19}F) = 2.3, C-4')$, 125.9 (C-6), 116.8 (C-8), 116.7 (C-4a). ¹⁹F NMR (282.38 MHz, DMSO-*d*6), δ (ppm): -61.02 (s, 3F, CF_3). ⁷⁷Se NMR (76.35 MHz, DMSO-*d*6), δ (ppm): 451.0 (s).

Synthesis of compounds 4a–g. To a solution (10 mmol) of the corresponding selon 3a-g in 100 mL of absolute ethanol, 1.7 mL of 30% hydrogen peroxide was added (15 mmol) and refluxed for 1 h, then cooled to 20 °C. The solid precipitated from the solution was separated by filtration, washed with ethanol (2 × 50 mL), and dried at 40 °C.



2,2'-diselane-1,2-diylbis(3-phenylquinazolin-4(3*H*)-one). Light brown solid (68%), mp 290 °C. Anal. Calcd. for C₂₈H₁₈N₄O₂Se₂: C 56.01%, H 3.02%, N 9.33%. Found: C 56.09; H 3.06; N 9.37. ESI⁺-MS, *m*/*z*: calcd for [C₂₈H₁₈N₄O₂Se₂+ H]⁺ 602.9838, found 602.9827 [C₂₈H₁₈N₄O₂Se₂+ H]⁺. IR (KBr, selected bands, sm⁻¹): 1685, 1544, 1468, 1261, 1201, 952, 770, 696. ¹H NMR (500 MHz, DMSO-*d*₆), δ (ppm): 8.05 (d, *J* = 8.0, 1H, H-5), 7.82 (t, 1H, H-7), 7.66 (m, 5H, Ph), 7.47 (t, 1H, H-6), 7.40 (d, J = 8.0, 1H, H-8).



2,2'-diselane-1,2-diylbis [3-(2-methylphenyl)-quinazolin-4(3*H*)-one]. Orange solid (79%), mp 230 °C. Anal. Calcd. for $C_{30}H_{22}N_4O_2Se_2$: C 57.33%, H 3.53%, N 8.91%. Found: C 57.22; H 3.56; N 8.79. ESI⁺-MS, *m*/*z*: calcd for $[C_{30}H_{22}N_4O_2Se_2 + H]^+$ 631.0152, found 631.0132 $[C_{30}H_{22}N_4O_2Se_2 + H]^+$. IR (KBr, selected bands, sm⁻¹): 1684, 1610, 1575, 1538, 1467, 1254, 1199, 763, 695. ¹H NMR (500 MHz, DMSO-*d*₆), δ (ppm): 8.10 (d, 1H, H-5), 7.83 (m, 1H, H-7), 7.42–7.65 (m, 6H, H-6, H-8, 4H Ar), 2.24, 2.34 (s, 3H, CH₃). ¹³C NMR (125.72 MHz, DMSO-*d*₆), δ (ppm): 160.30, 160.25 (C=O), 151.00, 151.62 (C-Se), 148.4 (C-8a), 137.4 137.5 (C-2'), 135.8, 135.9 (C-1'), 135.76, 135.73, (C-7), 131.9 (C-3'), 132.0 (CH Ar), 130.2 (CH Ar), 128.2 (CH Ar), 127.5 (C-6), 127.3 (C-5), 126.4, 126.6 (C-8), 120.1 (C-4a), 17.6, 17.7 (CH₃). ⁷⁷Se NMR (76.35 MHz, DMSO-*d*₆), δ (ppm): 522.3, 513.9 (s, 2Se).



2,2'-diselane-1,2-diylbis [3-(2-methoxyphenyl)-quinazolin-4(3*H*)-one]. Orange solid (91%), mp 277 °C. Anal. Calcd. for $C_{30}H_{22}N_4O_4Se_2$: C 54.56%, H 3.36%, N 8.48%. Found: 54.48; H 3.43; N 8.43. ESI⁺-MS, *m*/*z*: calcd for [$C_{30}H_{22}N_4O_4Se_2+H$]⁺ 663.0050, found 663.0043 [$C_{30}H_{22}N_4O_4Se_2+H$]⁺. IR (KBr, selected bands, sm⁻¹): 1680, 1541, 1498, 1465, 1263, 1021, 764, 695, 640. ¹H NMR (500 MHz, DMSO-*d*₆), δ (ppm): 8.07 (dd, *J* = 12.5, *J* = 2.5, 1H, H-5), 7.81 (m, 1H, H-7), 7.70 (m, 1H, H-4'), 7.61 (m, 1H, H-6'), 7.51 (t, 1H, H-6), 7.41 (d, 1H, H-8), 7.38 (d, 1H, H-3'), 7.23 (t, 1H, H-5'), 3.84, 3.85 (3H, c, OCH₃).



2,2'-diselane-1,2-diylbis [3-(3-methoxyphenyl)-quinazolin-4(3*H*)-one]. Orange solid (83%), mp 271 °C. Anal. Calcd. for $C_{30}H_{22}N_4O_4Se_2$: C 54.56%, H 3.36%, N 8.48%. Found: C 54.44; H 3.32; N 8.39. ESI⁺-MS, *m/z*: calcd for [$C_{30}H_{22}N_4O_4Se_2$ +H]⁺ 663.0050, found 663.0043 [$C_{30}H_{22}N_4O_4Se_2$ +H]⁺. IR (KBr, selected bands, sm⁻¹): 3067, 1695, 1603, 1539, 1464, 1268, 1236, 1199, 1032, 905, 839, 768, 690. ¹H NMR (500 MHz, DMSO-*d*₆), δ (ppm): 8.08 (d, 1H, H-5), 7.80 (t, 1H, H-7), 7.60 (t, 1H, H-5'), 7.50 (t, 1H, H-6); 7.44 (d, 1H, H-8); 7.20–7.33 (m, 3H, 3H Ar), 3.85 (s, 3H, OCH₃). ¹³C NMR (125.72 MHz, DMSO-*d*₆), δ (ppm): 160.61 (C=O), 160.55 (C-O), 153.3 (C-Se), 147.9 (C-8a), 138.4 (C-1'), 135.56 (C-7), 131.2 (C-5'), 127.2 (C-5, C-6), 126.5 (C-8), 121.7 (C-6'), 120.5 (C-4a), 117.1 (C-4'), 115.4 (C-2'), 56.1 (OCH₃). ⁷⁷Se NMR (76.35 MHz, DMSO-*d*₆), δ (ppm): 534.7 (s, 2Se).



2,2'-diselane-1,2-diylbis [3-(2-fluorophenyl)-quinazolin-4(3*H*)-one]. Orange—red solid (66%), mp 250 °C. Anal. Calcd. for C₂₈H₁₆F₂N₄O₂Se₂: C 52.85%, H 2.53%, N 8.80%. Found: C 52.79; H 2.46; N 8.69. ESI⁺-MS, *m*/*z*: calcd for [C₂₈H₁₆F₂N₄O₂Se₂+H]⁺ 638.9650, found 638.9636 [C₂₈H₁₆F₂N₄O₂Se₂+H]⁺. IR (KBr, selected bands, sm⁻¹): 1700, 1680, 1544, 1498, 1464, 1258, 1199, 1114, 951, 879, 771, 691, 638. ¹H NMR (500 MHz, DMSO-*d*₆), δ (ppm): 8.10 (d, *J* = 5.0, 1H, H-5), 7.70-7.82 (m, 2H, H-7, 1H Ar), 7.89 (m, 1H, 1H Ar), 7.65 (t, 1H, 1H Ar), 7.50–7.57 (m, 2H, H-6, 1H Ar), 7.48 (d, *J* = 8.0, 1H, H-8). ¹³C NMR (125.72 MHz, DMSO-*d*₆), δ (ppm): 160.2 (C=O), 158.1 (d, ¹*J*(¹³C-¹⁹*F*) = 252.5, C-2'-F_i); 151.2 (C-Se), 147.8 (C-8a), 136.0 (C-7), 132.0 (C-5'), 134.36 (d, ³*J*(¹³C-¹⁹*F*) = 7.6, C-6'), 127.7 (C-6), 127.3 (C-5), 126.6 (C-8), 126.4 (d, ²*J*(¹³C-¹⁹*F*) = 3.8, C-3'), 124.3 (d, ²*J*(¹³C-¹⁹*F*) = 12.5, C-1'), 119.8 (C-4a), 117.6 (d, ³*J*(¹³C-¹⁹*F*) = 18.8, C-4'). ¹⁹F NMR (282.38 MHz, DMSO-*d*6), δ (ppm): -120.27 (s, 1F). ⁷⁷Se NMR (76.35 MHz, DMSO-*d*6), δ (ppm): 535.6–533.8 (m, 2Se).



4f

2,2'-diselane-1,2-diylbis [3-(2-chlorophenyl)-quinazolin-4(3*H*)-one]. Cherry-red solid (87%), mp 255 °C. ESI⁺-MS, *m*/*z*: calcd for $[C_{28}H_{16}Cl_2N_4O_2Se_2+H]^+$ 670.9051, found 670.9042 $[C_{28}H_{16}Cl_2N_4O_2Se_2+H]^+$. IR (KBr, selected bands, sm⁻¹): 3076, 1683, 1542, 1466, 1335, 1262, 1246, 1198, 947, 979, 765, 695, 637. ¹H NMR (500 MHz, DMSO-*d*₆), δ (ppm): 8.10 (dd, *J* = 10.0, *J* = 1.5, 1H, H-5), 7.80–7.95 (m, 2H, H-7, H Ar), 7.77 (m, 1H, H Ar), 7.70 (m, 1H, H Ar), 7.53 (m, 1H, H-6), 7.49 (m,1H, H-6). ¹³C NMR (125.72 MHz, DMSO-*d*₆), δ (ppm): 160.0 (C=O), 150.9 (C-Se), 147.9 (C-8a), 136.0 (C-7), 134.2 (C, Ar), 133.6 (CH, Ar), 132.3 (CH, Ar), 131.2 (CH, Ar), 129.5 (CH, Ar), 127.6 (C-6), 127.3 (C-5), 126.7 (C-8), 120.0 (C-4a). ⁷⁷Se NMR (76.35 MHz, DMSO-*d*₆), δ (ppm): 532.5, 529.6, 528.5 (s, 2Se).



2,2'-diselane-1,2-diylbis [3-[2-chloro-5-(trifluoromethyl)phenyl]quinazolin-4(3*H*)-one]. Orange solid (59%), mp 210 °C. Anal. Calcd. for $C_{30}H_{14}Cl_2F_6N_4O_2Se_2$: C 44.74%, H 1.75%, N 6.96%. Found: C 44.66; H 1.66; N 6.87. ESI⁺-MS, *m*/*z*: calcd for [C₃₀H₁₄Cl₂F₆N₄O₂Se₂+H]⁺ 806.8799, found 806.8784 [C₃₀H₁₄Cl₂F₆N₄O₂Se₂+H]⁺. IR (KBr, selected bands, sm⁻¹): 1715, 1704, 1609, 1544, 1467, 1338, 1130, 1074, 959, 886, 847, 770, 694, 614. ¹H NMR (500 MHz, DMSO-*d*₆), δ (ppm): 8.53 (2 bs, 1H, H-6'), 8.16 (bs, 2H, H-3', H-4'), 8.12 (dd, *J* = 8.0, *J* = 1.2, 1H, H-5); 7.87 (m, 1H, H-7); 7.48–7.58 (m, 2H, H-6, H-8). ¹³C NMR (125.72 MHz, DMSO-*d*₆), δ (ppm): 160.1 (C=O), 149.8, 149.5 (C-Se), 147.8 (C-8a), 138.2 (C-1'), 136.1 (C-7), 135.2 (C-2'), 132.5 (C-3'), 130.37 (C-6'), 130.02 (k, ²*J*(¹³C,¹⁹F) = 33.2, C-5'), 129.8 (C-4'), 127.8 (C-5), 127.3 (C-6), 126.8 (C-8), 125.6 (κ, ¹*J*(¹³C-¹⁹*F*) = 271.3, CF₃), 120.0 (C-4a). ¹⁹F NMR (282.38 MHz, DMSO-*d*₆), δ (ppm): -61.09 (s, 3F, CF₃). ⁷⁷Se NMR (76.35 MHz, DMSO-*d*₆), δ (ppm): 536.8, 533.5 (s, 2Se).

3.2. Computational Details

The DFT calculations based on the experimental X-ray geometries of **3f**, **4b**, **4c**, **5**, **6**, **7**, and **8** were carried out using the dispersion-corrected hybrid functional *w*B97XD [66] with the help of Gaussian-09 [67] program package. The 6-311++G** basis sets were used for all atoms, except Te (for which quasi-relativistic MWB46 pseudopotentials [68], which described 46 core electrons, and the appropriate contracted basis sets were utilized). The topological analysis of the electron density distribution with the help of the quantum theory of atoms-in-molecules (QTAIM) method, electron localization function (ELF), reduced density gradient (RDG), and noncovalent interactions (NCI) analyses was performed by using the Multiwfn program (version 3.7) [69]. The VMD program [70] was used for the visualization of noncovalent interactions (NCI analysis). The Cartesian atomic coordinates for model supramolecular associates are presented in Table S1, Supplementary Materials.

4. Conclusions

In summary, we reported a convenient synthesis of series novel 2-selenoxo-1,2,3,4tetrahydro-4-quinazolinone via a reaction between methyl anthranilate and isoselenocyanates. These compounds were found to undergo facile oxidation to furnish corresponding diselenides in high yields. The structures and purity of all compounds were unambiguously established using the ¹H, ⁷⁷Se, and ¹³C NMR spectroscopies; high-resolution electrospray ionization mass spectrometry; IR; elemental analyses; and X-ray diffraction analysis for several of them. X-Ray single crystal analysis was performed for **3f**, **4b**, **4c**, **5**, **6**, **7**, and **8**, which revealed that selone **3f** featured the formation of unsymmetrical supramolecular dimers via type II Se…Se ChB, while **3b** and **3f** did not exhibit ChB interactions, arguably due to dominance of other weak interactions in the crystal. For compounds **4b** and **4c**, a pair of intramolecular Se…N ChB were found in the solid state. Such intramolecular ChB interactions are scarce—CCDC contained only four structures featuring such contacts. The existence of all the above-mentioned ChB was additionally confirmed by DFT calculations followed by the topological analysis of the electron density distribution.

Supplementary Materials: The following supporting information can be downloaded at: https: //www.mdpi.com/article/10.3390/molecules27185799/s1, Figure S1: Crystal packing of **3b** demonstrating the H-bonded chains of the crystallographically independent molecules **A**. Figure S2: Crystal packing of 3f demonstrating the ribbons towards the crystallographic c axis. Within the ribbons, the molecules are bound to each other by the strong N–H···O hydrogen bonds and weak nonvalent Se···Se interactions (Se1···Se2 [1–*x*, 2–*y*, 1–*z*] 3.7173(4) Å). Figure S3: The two projections of crystal packing of **3g** demonstrating the two-tier layer parallel to (010). Within the layer, the molecules are bound to each other by the N–H···Se hydrogen bonds as well as the nonvalent Se···O (Se2···O2 [1–*x*, -0.5+y, 1.5-z] 3.3702(16) Å) and Cl···F (Cl2···F1 [1–*x*, -0.5+y, 1.5-z] 3.0607(17) Å) interactions. Scheme S1. Plausible mechanism for the formation of **3a–g**. Table S1: Cartesian atomic coordinates for model supramolecular associates. Crystal structure determinations, Table S2: Crystal data and structure refinement for all compounds studied. References [71–74] are cited in Supplementary Materials.

Author Contributions: Conceptualization, A.V.B. and A.G.T.; methodology, A.V.B., V.K.O. and A.S.K.; investigation, A.S.N., E.V.C., V.K.O., V.N.K., R.K.A., A.O.C., G.N.B., M.M.G., M.N.K., A.A.K. and A.S.P.; writing—original draft preparation, A.S.N., V.K.O. and A.G.T.; writing—review and editing, A.S.N., V.K.O. and A.G.T.; supervision, A.V.B. All authors have read and agreed to the published version of the manuscript.

Funding: This work was performed under the support of the Russian Science Foundation (award no. 22-73-10007). X-Ray analysis was performed under the support of the RUDN University Strategic Academic Leadership Program. NMR analysis was carried out using the equipment of the Center for molecular composition studies of INEOS RAS.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References

- 1. Khan, I.; Ibrar, A.; Ahmed, W.; Saeed, A. Synthetic approaches, functionalization and therapeutic potential of quinazoline and quinazolinone skeletons: The advances continue. *Eur. J. Med. Chem.* **2015**, *90*, 124–169. [CrossRef] [PubMed]
- Asif, M. Chemical Characteristics, Synthetic Methods, and Biological Potential of Quinazoline and Quinazolinone Derivatives. Int. J. Med. Chem. 2014, 2014, 395637. [CrossRef]
- 3. Jafari, E.; Khajouei, M.; Hassanzadeh, F.; Hakimelahi, G.; Khodarahmi, G. Quinazolinone and quinazoline derivatives: Recent structures with potent antimicrobial and cytotoxic activities. *Res. Pharm. Sci.* **2016**, *11*, 1–14. [PubMed]
- Hameed, A.; Al-Rashida, M.; Uroos, M.; Ali, S.A.; Arshia; Ishtiaq, M.; Khan, K.M. Quinazoline and quinazolinone as important medicinal scaffolds: A comparative patent review (2011–2016). *Expert Opin. Ther. Pat.* 2018, 28, 281–297. [CrossRef] [PubMed]
- Moreno, E.; Plano, D.; Lamberto, I.; Font, M.; Encío, I.; Palop, J.A.; Sanmartín, C. Sulfur and selenium derivatives of quinazoline and pyrido [2,3-d]pyrimidine: Synthesis and study of their potential cytotoxic activity in vitro. *Eur. J. Med. Chem.* 2012, 47, 283–298. [CrossRef] [PubMed]
- Moreno, E.; Doughty-Shenton, D.; Plano, D.; Font, M.; Encío, I.; Palop, J.A.; Sanmartín, C. A dihydroselenoquinazoline inhibits S6 ribosomal protein signalling, induces apoptosis and inhibits autophagy in MCF-7 cells. *Eur. J. Pharm. Sci.* 2014, 63, 87–95. [CrossRef] [PubMed]
- Kasibhatla, S.; Baichwal, V.; Cai, S.X.; Roth, B.; Skvortsova, I.; Skvortsov, S.; Lukas, P.; English, N.M.; Sirisoma, N.; Drewe, J.; et al. MPC-6827: A Small-Molecule Inhibitor of Microtubule Formation That Is Not a Substrate for Multidrug Resistance Pumps. *Cancer Res.* 2007, 67, 5865–5871. [CrossRef] [PubMed]
- Sirisoma, N.; Pervin, A.; Zhang, H.; Jiang, S.; Willardsen, J.A.; Anderson, M.B.; Mather, G.; Pleiman, C.M.; Kasibhatla, S.; Tseng, B.; et al. Discovery of N-(4-Methoxyphenyl)-N,2-dimethylquinazolin-4-amine, a Potent Apoptosis Inducer and Efficacious Anticancer Agent with High Blood Brain Barrier Penetration. *J. Med. Chem.* 2009, 52, 2341–2351. [CrossRef] [PubMed]
- 9. Wu, X.; Li, M.; Qu, Y.; Tang, W.; Zheng, Y.; Lian, J.; Ji, M.; Xu, L. Design and synthesis of novel Gefitinib analogues with improved anti-tumor activity. *Bioorg. Med. Chem.* 2010, *18*, 3812–3822. [CrossRef]
- Hanusek, J.; Hejtmánková, L.; Kubicová, L.; Sedlák, M. Synthesis of Substituted 2-Benzoylaminothiobenzamides and Their Ring Closure to Substituted 2-Phenylquinazoline-4-thiones. *Molecules* 2001, *6*, 323–337. [CrossRef]

- 11. Kubicová, L.; Šustr, M.; Kráľová, K.; Chobot, V.; Vytlačilová, J.; Jahodář, L.; Vuorela, P.; Macháček, M.; Kaustová, J. Synthesis and Biological Evaluation of Quinazoline-4-thiones. *Molecules* **2003**, *8*, 756–769. [CrossRef]
- Niewiadomy, A.; Matysiak, J.; Karpińska, M.M. Synthesis and Anticancer Activity of New 2-Aryl-4H-3,1-benzothiazines. Arch. Pharm. Weinh. 2011, 344, 224–230. [CrossRef]
- Sancineto, L.; Iraci, N.; Massari, S.; Attanasio, V.; Corazza, G.; Barreca, M.L.; Sabatini, S.; Manfroni, G.; Avanzi, N.R.; Cecchetti, V.; et al. Computer-Aided Design, Synthesis and Validation of 2-Phenylquinazolinone Fragments as CDK9 Inhibitors with Anti-HIV-1 Tat-Mediated Transcription Activity. *ChemMedChem* 2013, *8*, 1941–1953. [CrossRef] [PubMed]
- 14. Häcker, H.-G.; Grundmann, F.; Lohr, F.; Ottersbach, P.A.; Zhou, J.; Schnakenburg, G.; Gütschow, M. 2-Amino- and 2-Alkylthio-4H-3,1-benzothiazin-4-ones: Synthesis, Interconversion and Enzyme Inhibitory Activities. *Molecules* **2009**, *14*, 378–402. [CrossRef]
- Komar, M.; Kraljević, T.G.; Jerković, I.; Molnar, M. Application of Deep Eutectic Solvents in the Synthesis of Substituted 2-Mercaptoquinazolin-4(3H)-Ones: A Comparison of Selected Green Chemistry Methods. *Molecules* 2022, 27, 558. [CrossRef] [PubMed]
- 16. Yadav, S.; Deka, R.; Singh, H.B. Recent Developments in the Chemistry of NHC-based Selones: Syntheses, Applications and Reactivity. *Chem. Lett.* **2018**, *48*, 65–79. [CrossRef]
- 17. Mammadova, G.Z.; Matsulevich, Z.V.; Osmanov, V.K.; Borisov, A.V.; Khrustalev, V.N. 1,3-Benzothia{\-}zole-2(3{\it H})-selone. Acta Crystallogr. Sect. E 2011, 67, o3050. [CrossRef] [PubMed]
- 18. Mammadova, G.Z.; Matsulevich, Z.V.; Osmanov, V.K.; Borisov, A.V.; Khrustalev, V.N. 1-Methyl-2,3-dihydro-1{\it H}benzimidazole-2-selone. *Acta Crystallogr. Sect. E* 2012, *68*, o1381. [CrossRef]
- 19. Alcolea, V.; Plano, D.; Encío, I.; Palop, J.A.; Sharma, A.K.; Sanmartín, C. Chalcogen containing heterocyclic scaffolds: New hybrids with antitumoral activity. *Eur. J. Med. Chem.* **2016**, *123*, 407–418. [CrossRef] [PubMed]
- Yun, L.M.; Shakhidoyatov, K.M. 2-Selenoxoquinazolones-4, a new kind of quinazolone. *Chem. Heterocycl. Compd.* 1986, 22, 345–346. [CrossRef]
- Šibor, J.; Žůrek, D.; Humpa, O.; Pazdera, P. Acid-Base Initiated Cyclization and Retrocyclization Reactions of Ethyl 2-(3-Acylselenoureido)benzoates, -thiophene-3-carboxylates and the Corresponding 2-(3-Acylisoselenoureido) Derivatives. *Molecules* 2000, *5*, 37–50. [CrossRef]
- 22. Atanassov, P.K.; Linden, A.; Heimgartner, H. Synthesis of 4-(Phenylamino)quinazoline-2(1H)-selones and Diselenides from Isoselenocyanates: Dimroth Rearrangement of an Intermediate. *Helv. Chim. Acta* 2004, *87*, 1873–1887. [CrossRef]
- Desiraju, G.R. Supramolecular Synthons in Crystal Engineering—A New Organic Synthesis. Angew. Chem. Int. Ed. Engl. 1995, 34, 2311–2327. [CrossRef]
- 24. Hobza, P.; Havlas, Z. Blue-Shifting Hydrogen Bonds. Chem. Rev. 2000, 100, 4253–4264. [CrossRef]
- 25. Eliseeva, A.A.; Ivanov, D.M.; Novikov, A.S.; Kukushkin, V.Y. Recognition of the *π*-hole donor ability of iodopentafluorobenzene–a conventional *σ*-hole donor for crystal engineering involving halogen bonding. *CrystEngComm* **2019**, *21*, 616–628. [CrossRef]
- Scheiner, S. The Pnicogen Bond: Its Relation to Hydrogen, Halogen, and Other Noncovalent Bonds. Acc. Chem. Res. 2013, 46, 280–288. [CrossRef] [PubMed]
- Murray, J.S.; Lane, P.; Clark, T.; Riley, K.E.; Politzer, P. σ-Holes, π-holes and electrostatically-driven interactions. *J. Mol. Model.* 2012, 18, 541–548. [CrossRef]
- Li, H.; Lu, Y.; Liu, Y.; Zhu, X.; Liu, H.; Zhu, W. Interplay between halogen bonds and π–π stacking interactions: CSD search and theoretical study. *Phys. Chem. Chem. Phys.* 2012, 14, 9948–9955. [CrossRef] [PubMed]
- 29. Nelyubina, Y.V.; Antipin, M.Y.; Lyssenko, K.A. Extremely short halogen bond: The nature and energy of iodine–oxygen interactions in crystalline iodic acid. *Mendeleev Commun.* **2011**, *21*, 250–252. [CrossRef]
- Metrangolo, P.; Neukirch, H.; Pilati, T.; Resnati, G. Halogen Bonding Based Recognition Processes: A World Parallel to Hydrogen Bonding. Acc. Chem. Res. 2005, 38, 386–395. [CrossRef] [PubMed]
- Li, Q.; Li, R.; Zhou, Z.; Li, W.; Cheng, J. S…X halogen bonds and H…X hydrogen bonds in H2CS–XY (XY = FF, CIF, CICI, BrF, BrCl, and BrBr) complexes: Cooperativity and solvent effect. J. Chem. Phys. 2012, 136, 14302. [CrossRef] [PubMed]
- 32. Tsirelson, V.G.; Zhou, P.F.; Tang, T.-H.; Bader, R.F.W. Topological definition of crystal structure: Determination of the bonded interactions in solid molecular chlorine. *Acta Crystallogr. Sect. A* **1995**, *51*, 143–153. [CrossRef]
- 33. Grabowski, S.J. Lewis Acid Properties of Tetrel Tetrafluorides—The Coincidence of the σ-Hole Concept with the QTAIM Approach. *Crystals* **2017**, 7, 43. [CrossRef]
- 34. Khrustalev, V.N.; Grishina, M.M.; Matsulevich, Z.V.; Lukiyanova, J.M.; Borisova, G.N.; Osmanov, V.K.; Novikov, A.S.; Kirichuk, A.A.; Borisov, A.V.; Solari, E.; et al. Novel cationic 1,2,4-selenadiazoles: Synthesis via addition of 2-pyridylselenyl halides to unactivated nitriles, structures and four-center Se. N contacts. *Dalt. Trans.* 2021, 50, 10689–10691. [CrossRef]
- Grudova, M.V.; Khrustalev, V.N.; Kubasov, A.S.; Strashnov, P.V.; Matsulevich, Z.V.; Lukiyanova, J.M.; Borisova, G.N.; Kritchenkov, A.S.; Grishina, M.M.; Artemjev, A.A.; et al. Adducts of 2-Pyridylselenenyl Halides and Nitriles as Novel Supramolecular Building Blocks: Four-Center Se…N Chalcogen Bonding versus Other Weak Interactions. *Cryst. Growth Des.* 2022, 22, 313–322. [CrossRef]
- Buslov, I.V.; Novikov, A.S.; Khrustalev, V.N.; Grudova, M.V.; Kubasov, A.S.; Matsulevich, Z.V.; Borisov, A.V.; Lukiyanova, J.M.; Grishina, M.M.; Kirichuk, A.A.; et al. 2-Pyridylselenenyl versus 2-Pyridyltellurenyl Halides: Symmetrical Chalcogen Bonding in the Solid State and Reactivity towards Nitriles. *Symmetry* 2021, 13, 2350. [CrossRef]

- Artemjev, A.A.; Novikov, A.P.; Burkin, G.M.; Sapronov, A.A.; Kubasov, A.S.; Nenajdenko, V.G.; Khrustalev, V.N.; Borisov, A.V.; Kirichuk, A.A.; Kritchenkov, A.S.; et al. Towards Anion Recognition and Precipitation with Water-Soluble 1,2,4-Selenodiazolium Salts: Combined Structural and Theoretical Study. *Int. J. Mol. Sci.* 2022, 23, 6372. [CrossRef] [PubMed]
- 38. Grudova, M.V.; Novikov, A.S.; Kubasov, A.S.; Khrustalev, V.N.; Kirichuk, A.A.; Nenajdenko, V.G.; Tskhovrebov, A.G. Aurophilic Interactions in Cationic Three-Coordinate Gold(I) Bipyridyl/Isocyanide Complex. *Crystals* **2022**, *12*, 613. [CrossRef]
- Khrustalev, V.N.; Savchenko, A.O.; Zhukova, A.I.; Chernikova, N.Y.; Kurykin, M.A.; Novikov, A.S.; Tskhovrebov, A.G. Attractive fluorine…fluorine interactions between perfluorinated alkyl chains: A case of perfluorinated Cu(II) diiminate Cu[C2F5-C(NH)-CF=C(NH)-CF3]2. Z. Fur Krist.-Cryst. Mater. 2021, 236, 117–122. [CrossRef]
- 40. Tskhovrebov, A.G.; Novikov, A.S.; Kritchenkov, A.S.; Khrustalev, V.N.; Haukka, M. Attractive halogen…halogen interactions in crystal structure of trans-dibromogold(III) complex. Z. Fur Krist.-Cryst. Mater. 2020, 235, 477–480. [CrossRef]
- Shikhaliyev, N.G.; Maharramov, A.M.; Suleymanova, G.T.; Babazade, A.A.; Nenajdenko, V.G.; Khrustalev, V.N.; Novikov, A.S.; Tskhovrebov, A.G. Arylhydrazones of α-keto esters via methanolysis of dichlorodiazabutadienes: Synthesis and structural study. *Mendeleev Commun.* 2021, *31*, 677–679. [CrossRef]
- Tskhovrebov, A.G.; Novikov, A.S.; Tupertsev, B.S.; Nazarov, A.A.; Antonets, A.A.; Astafiev, A.A.; Kritchenkov, A.S.; Kubasov, A.S.; Nenajdenko, V.G.; Khrustalev, V.N. Azoimidazole Gold(III) Complexes: Synthesis, Structural Characterization and Self-Assembly in the Solid State. *Inorg. Chim. Acta* 2021, 522, 120373. [CrossRef]
- Shikhaliyev, N.G.; Maharramov, A.M.; Bagirova, K.N.; Suleymanova, G.T.; Tsyrenova, B.D.; Nenajdenko, V.G.; Novikov, A.S.; Khrustalev, V.N.; Tskhovrebov, A.G. Supramolecular organic frameworks derived from bromoaryl-substituted dichlorodiazabutadienes via Cl…Br halogen bonding. *Mendeleev Commun.* 2021, *31*, 191–193. [CrossRef]
- 44. Tsyrenova, B.; Nenajdenko, V. Synthesis and spectral study of a new family of 2,5-diaryltriazoles having restricted rotation of the 5-aryl substituent. *Molecules* 2020, 25, 480. [CrossRef] [PubMed]
- Repina, O.V.; Novikov, A.S.; Khoroshilova, O.V.; Kritchenkov, A.S.; Vasin, A.A.; Tskhovrebov, A.G. Lasagna-like supramolecular polymers derived from the PdII osazone complexes via C(sp2)–H··· Hal hydrogen bonding. *Inorg. Chim. Acta* 2020, 502, 119378. [CrossRef]
- Mikhaylov, V.N.; Sorokoumov, V.N.; Novikov, A.S.; Melnik, M.V.; Tskhovrebov, A.G.; Balova, I.A. Intramolecular hydrogen bonding stabilizes trans-configuration in a mixed carbene/isocyanide PdII complexes. *J. Organomet. Chem.* 2020, 912, 121174. [CrossRef]
- Nenajdenko, V.G.; Shikhaliyev, N.G.; Maharramov, A.M.; Atakishiyeva, G.T.; Niyazova, A.A.; Mammadova, N.A.; Novikov, A.S.; Buslov, I.V.; Khrustalev, V.N.; Tskhovrebov, A.G. Structural Organization of Dibromodiazadienes in the Crystal and Identification of Br…O Halogen Bonding Involving the Nitro Group. *Molecules* 2022, 27, 5110. [CrossRef] [PubMed]
- Liu, Y.; Varava, P.; Fabrizio, A.; Eymann, L.Y.M.; Tskhovrebov, A.G.; Planes, O.M.; Solari, E.; Fadaei-Tirani, F.; Scopelliti, R.; Sienkiewicz, A.; et al. Synthesis of aminyl biradicals by base-induced Csp3–Csp3 coupling of cationic azo dyes. *Chem. Sci.* 2019, 10, 5719–5724. [CrossRef] [PubMed]
- 49. Palmer, J.H.; Parkin, G. 2-Seleno-1-alkylbenzimidazoles and their diselenides: Synthesis and structural characterization of a 2-seleno-1-methylbenzimidazole complex of mercury. *Polyhedron* **2013**, *52*, 658–668. [CrossRef]
- Antoniadis, C.D.; Blake, A.J.; Hadjikakou, S.K.; Hadjiliadis, N.; Hubberstey, P.; Schröder, M.; Wilson, C. Structural characterization of selenium and selenium-diiodine analogues of the antithyroid drug 6-{\it n}-propyl-2-thiouracil and its alkyl derivatives. *Acta Crystallogr. Sect. B* 2006, 62, 580–591. [CrossRef] [PubMed]
- Bhasin, K.K.; Arora, E.; Grover, A.S.; Jyoti; Singh, H.; Mehta, S.K.; Bhasin, A.K.K.; Jacob, C. Synthesis and characterization of new 2-pyrimidyl chalcogen (S, Se, Te) compounds: X-ray crystal structure of bis(4,6-dimethyl-2-pyrimidyl)diselenide and 4,6-dimethyl-2-(phenylselanyl)pyrimidine. *J. Organomet. Chem.* 2013, 732, 137–141. [CrossRef]
- 52. Borisov, A.V.; Matsulevich, Z.V.; Osmanov, V.K.; Borisova, G.N.; Chizhov, A.O.; Mammadova, G.Z.; Maharramov, A.M.; Aisin, R.R.; Khrustalev, V.N. Diorganyl dichalcogenides with intramolecular coordination interactions: The synthesis and structure of bis(4,6-dimethylpyrimidin-2-yl) diselenide. *Russ. Chem. Bull.* **2013**, *62*, 2462–2466. [CrossRef]
- 53. Bader, R.F.W. A Quantum Theory of Molecular Structure and Its Applications. Chem. Rev. 1991, 91, 893–928. [CrossRef]
- 54. Johnson, E.R.; Keinan, S.; Mori-Sánchez, P.; Contreras-García, J.; Cohen, A.J.; Yang, W. Revealing noncovalent interactions. J. Am. Chem. Soc. 2010, 132, 6498–6506. [CrossRef] [PubMed]
- 55. Espinosa, E.; Molins, E.; Lecomte, C. Hydrogen bond strengths revealed by topological analyses of experimentally observed electron densities. *Chem. Phys. Lett.* **1998**, *285*, 170–173. [CrossRef]
- 56. Bondi, A. Van der Waals volumes and radii of metals in covalent compounds. J. Phys. Chem. 1966, 70, 3006–3007. [CrossRef]
- Grudova, M.V.; Kubasov, A.S.; Khrustalev, V.N.; Novikov, A.S.; Kritchenkov, A.S.; Nenajdenko, V.G.; Borisov, A.V.; Tskhovrebov, A.G. Exploring Supramolecular Assembly Space of Cationic 1,2,4-Selenodiazoles: Effect of the Substituent at the Carbon Atom and Anions. *Molecules* 2022, 27, 1029. [CrossRef] [PubMed]
- 58. Novikov, A.S.; Gushchin, A.L. Trinuclear molybdenum clusters with sulfide bridges as potential anionic receptors via chalcogen bonding. *CrystEngComm* **2021**, 23, 4607–4614. [CrossRef]
- Mikherdov, A.S.; Novikov, A.S.; Kinzhalov, M.A.; Zolotarev, A.A.; Boyarskiy, V.P. Intra-/Intermolecular Bifurcated Chalcogen Bonding in Crystal Structure of Thiazole/Thiadiazole Derived Binuclear (Diaminocarbene)PdII Complexes. Crystals 2018, 8, 112. [CrossRef]

- Mikherdov, A.S.; Novikov, A.S.; Kinzhalov, M.A.; Boyarskiy, V.P.; Starova, G.L.; Ivanov, A.Y.; Kukushkin, V.Y. Halides Held by Bifurcated Chalcogen–Hydrogen Bonds. Effect of μ(S,N–H)Cl Contacts on Dimerization of Cl(carbene)PdII Species. *Inorg. Chem.* 2018, 57, 3420–3433. [CrossRef]
- 61. Pairan, N.F.; Kasim, N.A.M.; Yamin, B.M.; Shah, N.A.A. Crystal structure of (E)-N,N-diethyl-2-(5-nitrothiazol-2-yl)-1-phenylethen-1-amine, C15H17N3O2S. Z. Für Krist.-New Cryst. Struct. 2017, 232, 795–797. [CrossRef]
- Mikherdov, A.S.; Kinzhalov, M.A.; Novikov, A.S.; Boyarskiy, V.P.; Boyarskaya, I.A.; Dar'In, D.V.; Starova, G.L.; Kukushkin, V.Y. Difference in Energy between Two Distinct Types of Chalcogen Bonds Drives Regioisomerization of Binuclear (Diaminocarbene)PdII Complexes. *J. Am. Chem. Soc.* 2016, 138, 14129–14137. [CrossRef] [PubMed]
- Contreras-García, J.; Johnson, E.R.; Keinan, S.; Chaudret, R.; Piquemal, J.-P.; Beratan, D.N.; Yang, W. NCIPLOT: A Program for Plotting Noncovalent Interaction Regions. J. Chem. Theory Comput. 2011, 7, 625–632. [CrossRef] [PubMed]
- 64. Espinosa, E.; Alkorta, I.; Elguero, J.; Molins, E. From weak to strong interactions: A comprehensive analysis of the topological and energetic properties of the electron density distribution involving X-H···F-Y systems. J. Chem. Phys. 2002, 117, 5529–5542. [CrossRef]
- 65. Zakrzewski, J.; Huras, B.; Kiełczewska, A. Synthesis of Isoselenocyanates. Syntheses 2016, 48, 85–96. [CrossRef]
- Chai, J.-D.; Head-Gordon, M. Long-range corrected hybrid density functionals with damped atom–atom dispersion corrections. *Phys. Chem. Chem. Phys.* 2008, 10, 6615–6620. [CrossRef]
- 67. Frisch, M.J.; Trucks, G.W.; Schlegel, H.B.; Scuseria, G.E.; Robb, M.A.; Cheeseman, J.R.; Scalmani, G.; Barone, V.; Mennucci, B.; Petersson, G.A.; et al. *Gaussian 09 C.01*; Gaussian Inc.: Wallingford, CT, USA, 2010.
- Bergner, A.; Dolg, M.; Küchle, W.; Stoll, H.; Preuß, H. Ab initio energy-adjusted pseudopotentials for elements of groups 13–17. *Mol. Phys.* 1993, *80*, 1431–1441. [CrossRef]
- 69. Lu, T.; Chen, F. Multiwfn: A multifunctional wavefunction analyzer. J. Comput. Chem. 2012, 33, 580–592. [CrossRef] [PubMed]
- 70. Humphrey, W.; Dalke, A.; Schulten, K. VMD: Visual molecular dynamics. J. Mol. Graph. 1996, 14, 33–38. [CrossRef]
- 71. Rigaku. CrysAlisPro Software System, v. 1.171.41.106a; Rigaku Oxford Diffraction: Tokyo, Japan, 2021.
- 72. Bruker. SAINT, v. 8.34A; Bruker AXS Inc.: Madison, WI, USA, 2014.
- 73. Krause, L.; Herbst-Irmer, R.; Sheldrick, G.M.; Stalke, D. Comparison of silver and molybdenum microfocus X-ray sources for single-crystal structure determination. *J. Appl. Cryst.* **2015**, *48*, 3–10. [CrossRef]
- 74. Sheldrick, G.M. Crystal structure refinement with SHELXL. Acta Cryst. 2015, C71, 3–8. [CrossRef]